Treatment persistence of interleukin-17 inhibitor class drugs among patients with psoriasis in Japan: a retrospective database study.

BACKGROUND AND OBJECTIVE Real-world evidence on persistence of interleukin-17 inhibitors (IL-17i) as a drug class among Japanese patients with psoriasis is lacking. Hence, we aimed to describe persistence rates of IL-17is among patients with psoriasis including psoriasis vulgaris (PsO), psoriatic arthritis (PsA), and generalized pustular psoriasis (GPP) or erythrodermic psoriasis (EP) in Japan. METHODS We analyzed claims data from the Medical Data Vision database. Patients ≥15 years old with a psoriasis diagnosis and an IL-17i prescription between November 2016 and August 2020 were included and followed through August 2021. Persistence rates of the IL-17i class among patients with psoriasis and its subtypes (PsO, PsA, and GPP or EP), and persistence rates of ixekizumab, secukinumab, or brodalumab among patients with PsO or PsA were analyzed using Kaplan-Meier method. Analyses were conducted in the bio-naïve and bio-experienced subgroups. RESULTS The IL-17i class had >50% persistence rates up to 36 months among patients with psoriasis and its subtypes (PsO, PsA, and GPP or EP). 36-Month persistence rates for ixekizumab, secukinumab, and brodalumab were 46.2% to 57.7% in patients with PsO and 43.0% to 48.4% in patients with PsA. Across analyses, bio-naïve patients demonstrated similar or greater persistence rates than bio-experienced patients. CONCLUSION IL-17is' persistence rates over 36 months were >50% among patients with psoriasis and its subtypes (PsO, PsA, and GPP or EP) in Japan.

[1]  M. Komine,et al.  English version of Japanese guidance for use of biologics for psoriasis (the 2022 version) , 2022, The Journal of dermatology.

[2]  K. Tsuritani,et al.  Treatment patterns, healthcare resource utilization, and costs in patients with moderate‐to‐severe psoriasis treated with systemic therapy in Japan: A retrospective claims database study , 2022, The Journal of dermatology.

[3]  C. Griffiths,et al.  Drug Survival Associated With Effectiveness and Safety of Treatment With Guselkumab, Ixekizumab, Secukinumab, Ustekinumab, and Adalimumab in Patients With Psoriasis. , 2022, JAMA dermatology.

[4]  M. Tichý,et al.  Efficacy, safety, and drug survival of patients with psoriasis treated with IL-17 inhibitors – brodalumab, ixekizumab, and secukinumab: real-world data from the Czech Republic BIOREP registry , 2022, The Journal of dermatological treatment.

[5]  R. Burge,et al.  Real-World Biologic Adherence, Persistence, and Monotherapy Comparisons in US Patients with Psoriasis: Results from IBM MarketScan® Databases , 2022, Advances in Therapy.

[6]  Y. Tada,et al.  Impact of the COVID‐19 pandemic on biologic treatment in psoriasis patients: A single‐center retrospective study in Japan , 2022, The Journal of dermatology.

[7]  L. Penso,et al.  Long-term Persistence of First-line Biologics for Patients With Psoriasis and Psoriatic Arthritis in the French Health Insurance Database. , 2022, JAMA dermatology.

[8]  D. Sangiorgi,et al.  Analysis of the Pharmacoutilization of Biological Drugs in Psoriatic Arthritis Patients: A Real-World Retrospective Study Among an Italian Population , 2022, Rheumatology and Therapy.

[9]  R. Burge,et al.  A Retrospective Cohort Analysis of Treatment Patterns Over 1 Year in Patients with Psoriasis Treated with Ixekizumab or Guselkumab , 2022, Dermatology and Therapy.

[10]  L. Skov,et al.  Drug survival of biologics and novel immunomodulators for rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, and psoriasis - A nationwide cohort study from the DANBIO and DERMBIO registries. , 2022, Seminars in arthritis and rheumatism.

[11]  S. Feldman,et al.  Drug Adherence and Persistence of Patients with Moderate to Severe Psoriasis Treated with Biologic Medications in a US Commercially Insured Population , 2021, Dermatology.

[12]  G. Argenziano,et al.  Real‐world evidence of biologic treatments in moderate–severe psoriasis in Italy: Results of the CANOVA (EffeCtiveness of biologic treAtmeNts for plaque psOriasis in Italy: An obserVAtional longitudinal study of real‐life clinical practice) study , 2021, Dermatologic therapy.

[13]  S. Feldman,et al.  Treatment adherence and persistence of seven commonly prescribed biologics for moderate to severe psoriasis and psoriatic arthritis in a U.S. commercially insured population , 2021, The Journal of dermatological treatment.

[14]  L. Teixeira,et al.  Drug Survival of IL-12/23, IL-17 and IL-23 Inhibitors for Psoriasis Treatment: A Retrospective Multi-Country, Multicentric Cohort Study , 2021, American Journal of Clinical Dermatology.

[15]  J. Walsh,et al.  Treatment Persistence and Adherence Among Patients With Psoriatic Arthritis Who Initiated Targeted Immune Modulators in the US: A Retrospective Cohort Study , 2021, Advances in Therapy.

[16]  A. Kawada,et al.  Epidemiological survey of the psoriasis patients in the Japanese Society for Psoriasis Research from 2013 to 2018 , 2021, The Journal of dermatology.

[17]  B. Strober,et al.  Drug survival of ixekizumab, TNF inhibitors, and other IL‐17 inhibitors in real‐world patients with psoriasis: The Corrona Psoriasis Registry , 2021, Dermatologic therapy.

[18]  S. Dias,et al.  Patient characteristics as effect modifiers for psoriasis biologic treatment response: an assessment using network meta-analysis subgroups , 2020, Systematic Reviews.

[19]  B. Ohyama,et al.  Real‐world efficacy and safety of interleukin‐17 inhibitors for psoriasis: A single‐center experience , 2020, The Journal of dermatology.

[20]  R. Burge,et al.  Comparison of Real-World Treatment Patterns among Psoriasis Patients Prescribed Ixekizumab or Secukinumab. , 2019, Journal of the American Academy of Dermatology.

[21]  M. Komine,et al.  Drug survival of biologic agents for psoriatic patients in a real‐world setting in Japan , 2019, The Journal of dermatology.

[22]  S. Imafuku,et al.  Sustainability and switching of biologics for psoriasis and psoriatic arthritis at Fukuoka University Psoriasis Registry , 2019, The Journal of dermatology.

[23]  Y. Tada,et al.  Patient preference for biologic treatments of psoriasis in Japan , 2019, The Journal of dermatology.

[24]  J. Mahlich,et al.  Persistence rates and medical costs of biological therapies for psoriasis treatment in Japan: a real-world data study using a claims database , 2018, BMC Dermatology.

[25]  H. Nakagawa,et al.  Epidemiological survey of patients with psoriasis in Matsumoto city, Nagano Prefecture, Japan , 2018, The Journal of dermatology.

[26]  L. French,et al.  Superiority in Quality of Life Improvement of Biologics over Conventional Systemic Drugs in a Swiss Real-Life Psoriasis Registry , 2017, Dermatology.

[27]  Daisuke Koide,et al.  Epidemiology of psoriasis and palmoplantar pustulosis: a nationwide study using the Japanese national claims database , 2015, BMJ Open.

[28]  H. Quan,et al.  Coding Algorithms for Defining Comorbidities in ICD-9-CM and ICD-10 Administrative Data , 2005, Medical care.